Pharmaceuticals company Laurus Labs announced Q4FY25 & FY25 results Q4FY25 Financial Highlights: Revenues: Rs 1,720 crore compared to Rs 1,440 crore during Q4FY24, change 19%. EBITDA: Rs 477 crore compared to Rs 259 crore during Q4FY24, change 84%. EBITDA margin: 27.7% for Q4FY25. PBT: Rs 312 crore compared to Rs 107 crore during Q4FY24, change 192%. PAT: Rs 234 crore compared to Rs 76 crore during Q4FY24, change 208%. EPS: Rs 4.3 for Q4FY25. FY25 Financial Highlights: Revenues: Rs 5,554 crore compared to Rs 5,041 crore during FY24, change 10%. EBITDA: Rs 1,115 crore compared to Rs 798 crore during FY24, change 40%. EBITDA margin: 20.1% for FY25. PBT: Rs 484 crore compared to Rs 236 crore during FY24, change 105%. PAT: Rs 358 crore compared to Rs 161 crore during FY24, change 122%. EPS: Rs 6.6 for FY25. Satyanarayana Chava, Founder & Chief Executive Officer, said: “We delivered a very good Q4 results and continued our transformative progress, reflecting robust demand for our CDMO offerings and meeting complex customer needs, supported by growth in FDF division. These results demonstrate the strength of our business model and give us confidence in our outlook. We are deepening our cooperation with major clients, and augmenting it with promising BD and capacity creation. Our business remains well positioned to evolve into a well-diversified CMO/CDMO company with promising pipeline, enabling several technology platforms and commercial excellence, thanks to team commitment to the unified vision of delivering high quality integrated solution and securing our long-term growth potential.” V V Ravi Kumar, Executive Director & Chief Financial Officer, said: “Despite the ongoing macroeconomic challenges, we have witnessed high level of demand for our offerings. For Q4, we delivered Rs 1,720 crore in revenues, growth of 19% and Rs 477 crore EBITDA grew by 84%, resulting in 27.7% margin. Gross margins remained healthy at 55% due to favorable CDMO mix and process optimization measures. The fundamentals of our business remain healthy. Overall FY25 results, we have delivered revenues of Rs 5,554 crore, representing 10% growth and EBITDA stood at Rs 1,115 crore, growth of 40%. The EBITDA margin of 20.1% has substantially improved, supported by continuing operating leverage within CDMO business. Going ahead, we remain confident in our growth expectations as we look forward to execute on long lead programs, new assets ramp up with revenue increasing over FY25 with continued focus on operational excellence. Our capital allocation strategy remain unchanged, prioritizing investments into high value business opportunities.” Result PDF